Article
AAV Capsid Engineering — The CMC Implications of Novel Serotypes and Synthetic Capsid Variants
The AAV capsid engineering field is delivering synthetic variants with improved tissue selectivity, reduced immunogenicity, and higher transduction efficiency compared to natural serotypes. What the field is not…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
AAV Capsid Engineering — The CMC Implications of Novel Serotypes and Synthetic Capsid Variants
The AAV capsid engineering field is delivering synthetic variants with improved tissue selectivity, reduced immunogenicity, and higher transduction efficiency compared to natural serotypes. What the field is not…
Article
CMC Strategy for 505(b)(2) Applications — The Hybrid Pathway That Reduces Development Risk
The 505(b)(2) pathway reduces clinical development risk — it does not reduce CMC development risk. Every 505(b)(2) sponsor who begins CMC development with the assumption that the reference…
Article
Emerging GT Modalities — mRNA, CRISPR, Base Editing: CMC at the Next Frontier
The CMC frameworks developed for AAV and lentiviral vectors are being applied to mRNA-based gene therapies, CRISPR/Cas9 delivery systems, and engineered virus-like particles — sometimes correctly, often not.
Article
FDA Chemistry Review Timelines — Understanding the Review Clock and Where CMC Packages Get Stuck
Every NDA and BLA submission team watches the PDUFA action date. What most teams do not watch with the same precision is the OPQ chemistry review clock —…
Article
In Vivo vs Ex Vivo Gene Therapy — Why Drug Product Definition Changes Everything
The CMC requirements for an AAV delivered intravenously are not the same as for an ex vivo-transduced cellular product infused back into a patient. Treating them identically is…
Article
Comparability Protocol Strategy — Pre-Approved Protocols and When They Change Your Supplement Type
A comparability protocol is not a risk management document — it is a binding regulatory contract. When FDA pre-approves a CP, the agency is committing to accept a…
Article
CBER and EMA CAT — Regulatory Differences That Shape Your Global GT CMC Strategy
A gene therapy CMC package optimized for CBER will not automatically satisfy the EMA's Committee for Advanced Therapies. The differences are not cosmetic — they are substantive enough…
Article
Phase-Appropriate CMC — IND Phase 1 Through Phase 3: What FDA Actually Expects at Each Stage
Phase-appropriate CMC is not a framework for doing less CMC work. It is a framework for doing the right CMC work at the right phase — where "right"…
Article
Analytical Method Validation for GT — Meeting ICH Q2(R2) for Vector-Specific Methods
The analytical methods used to release and characterize a gene therapy vector are unlike any other in the pharmaceutical industry. Validating them to ICH Q2(R2) standards requires a…
Article
Lifecycle Management of Post-Approval Changes — ICH Q12 and the PACMP Architecture
Every Post-Approval Change Management Protocol is written as if it will be approved. Most of them earn the filing category they were designed to avoid. The PACMP is…
Article
From GT IND to BLA — The CMC Development Strategy That Avoids Phase 3 Catch-Up
Most gene therapy programs enter Phase 3 with CMC packages designed for Phase 1. The cost of catching up — analytically, regulatorily, and temporally — is measured in…
Article
ICH Q12 Established Conditions — Implementation Strategy for Marketed Drug Products
ICH Q12 has been final guidance in the United States since 2021, and FDA has published implementation considerations for FDA-regulated products. Yet the majority of marketed drug product…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.